CTOR

2.39% 0.0201

Handel nachbörslich: .86

Citius Oncology Inc (CTOR)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Citius Oncology Inc Stock (CTOR) Company Profile

Citius Oncology Inc

Healthcare (1111)

(908) 967-6677

11 COMMERCE DRIVE, CRANFORD

Nächster Verdiensttermin

Neueste SEC-Einreichungen

CTOR's Discussions on Twitter

Compare CTOR vs TAK, HLN, TEVA, ZTS, UTHR

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CTOR Citius Oncology Inc	0.86	78.09M	5.61M	-42.51M	-16.86M	-0.466
TAK Takeda Pharmaceutical Co Adr	15.87	51.34B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.24	41.15B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	34.61	39.67B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	80.23	34.09B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	578.43	24.13B	3.17B	1.29B	1.01B	27.09

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-09-23	Hochstufung	Maxim Group	Hold → Buy
2024-11-27	Eingeleitet	Maxim Group	Buy

Citius Oncology Inc Aktie (CTOR) Neueste Nachrichten

Finanzdaten der Citius Oncology Inc-Aktie (CTOR)

Citius Oncology Inc (CTOR)

Citius Oncology Inc Stock (CTOR) Company Profile

Compare CTOR vs TAK, HLN, TEVA, ZTS, UTHR

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

Citius Oncology Inc Aktie (CTOR) Neueste Nachrichten

Number of shareholders of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView

Citius Oncology study combining LYMPHIR with pembrolizumab selected for ASCO presentation - Investing.com Nigeria

Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting - PR Newswire

Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts? - Yahoo Finance

TENK News & Events - Intellectia AI

Citius Pharmaceuticals (NASDAQ: CTXR) registers 5.43M resale shares from warrants - Stock Titan

Citius Oncology (CTOR) registers 6.82M warrant shares; May 2026 financing steps - Stock Titan

CTOR Technical Analysis | Trend, Signals & Chart Patterns | CITIUS ONCOLOGY INC (NASDAQ:CTOR) - ChartMill

CTXR Stock Price, Quote & Chart | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill

Citius Oncology (NASDAQ: CTOR) majority approves warrant and conversion issuances - Stock Titan

Citius Pharmaceuticals Reports Increased Losses in Q2 FY 2026 - Intellectia AI

Is Citius Pharmaceuticals (CTXR) Undervalued After Q2 FY2026 Upd - GuruFocus

Citius Oncology Inc reports results for the quarter ended March 31Earnings Summary - TradingView

Citius Oncology reports $5.6M H1 revenue, $26.6M Q2 net loss; secures up to $36.5M financing - TradingView

[8-K] CITIUS ONCOLOGY, INC. Reports Material Event - Stock Titan

Citius Pharmaceuticals (CTXR) logs $5.6M LYMPHIR sales, deeper losses in Q2 2026 - Stock Titan

CITIUS ONCOLOGY, INC. 3Q 2026: Revenue $1.67M, EPS $(0.27) — 10-Q Summary - TradingView

Citius Oncology 2Q Loss/Shr 27c >CTOR - Moomoo

Citius Pharmaceuticals (CTXR) starts LYMPHIR sales but faces heavy loss and going concern risk - Stock Titan

Citius Oncology (NASDAQ: CTOR) flags going concern, adds $25.0 million loan - Stock Titan

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update - PR Newswire

Armistice Capital (CTOR) files 9.99% ownership disclosure - Stock Titan

TradingKey - TradingKey

Citius Oncology, Inc. (CTOR) Eps Diluted (TTM) - Zacks Investment Research

Citius Pharmaceuticals Announces Third Amendment to Promissory Note with Citius Oncology – SEC Filing Details - Minichart

Citius Pharmaceuticals Amends Promissory Note to Enhance Flexibility - TipRanks

Citius Oncology Inc expected to post a loss of 1 cent a shareEarnings Preview - TradingView

Citius Pharmaceuticals (CTXR) adds $0.90 share conversion to $3.8M note - Stock Titan

What Citius Oncol (CTOR) is doing to protect its market share (On the Radar) 2026-05-08Revenue Growth Stocks - newser.com

Financing package boosts Lymphir commercial push - The Pharma Letter

Citius Pharmaceuticals subsidiary raises up to 36.5 million dollars for LYMPHIR commercialization - Traders Union

Citius Oncology Secures New Financing to Support LYMPHIR - TipRanks

Citius Oncology Secures $36.5 Million Financing to Accelerate LYMPHIR® Commercialization and Growth - Minichart

Citius raises $36.5m for Lymphir commercialisation - Yahoo Finance

Citius Oncology Secures Up to $25M Term Loan and $11.5M Warrant Proceeds to Fund Commercialization - TradingView

Press Release: Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR(R) Commercialization - Moomoo

Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules - Quantisnow

Citius Oncology (NASDAQ: CTOR) registers 6.82M warrant shares, updates LYMPHIR trials and launch - Stock Titan

Citius Oncology, Inc. announced that it expects to receive $36.5 million in funding - marketscreener.com

Citius Oncology Faces Nasdaq Non-Compliance, Delisting Risk Looms - TipRanks

CTOR Stock Price, Quote & Chart | CITIUS ONCOLOGY INC (NASDAQ:CTOR) - ChartMill

Citius Oncology sees first international shipment of LYMPHIR to Europe - ROI-NJ

Citius Oncology, Inc.'s (NASDAQ:CTOR) Path To Profitability - simplywall.st

Citius Expands LYMPHIR Access with First European Shipment - TipRanks

Citius Oncology Begins First European Expansion of LYMPHIR - TipRanks

Citius Oncology ships first international order of LYMPHIR to Europe - TradingView

Citius Oncology Shares Climb Following Expansion of LYMPHIR Distribution Network - MSN

Citius Oncology Ships First International Order of LYMPHIR™ to E - GuruFocus

Citius Oncology Ships First International Order of LYMPHIR™ to Europe - ChartMill

Citius Oncology, Inc. Receives Nasdaq Compliance Notice for CTOR Common Stock – Form 8-K April 2026 Filing - Minichart

Citius Oncology Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView

Finanzdaten der Citius Oncology Inc-Aktie (CTOR)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie CTOR